CTNM vs MPLT: stock comparison and AI forecast
Contineum Therapeutics, Inc. (CTNM) and Maplight Therapeutics, Inc. (MPLT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CTNM Contineum Therapeutics, Inc.
- Market Cap
- $360M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MPLT Maplight Therapeutics, Inc.
- Market Cap
- $377M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CTNM and MPLT have similar market capitalizations ($360M and $377M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CTNM | MPLT |
|---|---|---|
| Market Cap | $360M | $377M |
| P/B Ratio | – | 1.08x |
| EPS | $-3.14 | $-21.22 |
| Book Value/Share | – | $6.27 |
| FCF/Share | $-1.42 | $-4.22 |
Profitability & Margins
| Metric | CTNM | MPLT |
|---|---|---|
| ROIC | – | -85.1% |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | CTNM | MPLT |
|---|---|---|
| Current Ratio | 37.17x | 16.52x |
| D/E Ratio | – | 0.06x |
| Financial Leverage | – | 1.06x |
| Working Capital | $236M | $299M |
Cash Flow
| Metric | CTNM | MPLT |
|---|---|---|
| Operating Cash Flow | -$53M | -$234M |
| Free Cash Flow | -$53M | -$235M |
| Capital Spending | -$460K | -$520K |
Income Statement
| Metric | CTNM | MPLT |
|---|---|---|
| Operating Income | -$66M | -$297M |
| R&D Expense | $48M | $245M |
Dividend & Shareholder Information
| Metric | CTNM | MPLT |
|---|---|---|
| Shares Outstanding | 38M | 56M |
CTNM vs MPLT: stock comparison and AI forecast
Which is bigger, CTNM or MPLT?
CTNM and MPLT have similar market capitalizations ($360M and $377M).
Which one does Intratio's AI model rank higher, CTNM or MPLT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.